Bactiguard’s noble metal coating has a unique property that reduces microbial adhesion to the surface of medical devices. Previous studies have hinted at its ability to reduce thrombo-inflammatory reactions.
This particular study was conducted to gather more clinical data and evidence regarding the coating’s effectiveness. For innovation and future application development, two versions of the coating were applied to the stents in the study: Bactiguard’s “standard” coating consisting of gold, silver, and palladium, and a modified version including neodymium.
Advertisement
The study used both in vivo (in pigs) and in vitro methods (blood marker analysis, including human samples). Pigs underwent blinded implantation of both coated and non-coated stents, with the interventionist unaware of which stents were coated. The experiment concluded after two hours, representing the acute implantation phase.
Stents were placed in the lingual artery, with one coated and one uncoated on each side. CT-scan data was used to analyze stent volume, performed by an assessor blinded to the treatment. Laboratory tests were conducted using both human and pig blood, with all human participants providing consent.
Measurements revealed that the coated stent group exhibited a significant reduction in blood clot volume compared to the control group. This effect was noticeable as early as one hour after stent implantation and became more pronounced after two hours. In vitro data, using both human and pig blood, showed a marked decrease in coagulation and inflammation markers in the coated group compared to the control group.
Dr. Stefan Grass, Chief Medical Officer at Bactiguard, commented, “The findings of this study are promising and provide crucial data supporting the efficacy of Bactiguard’s coating. The combination of infection prevention without an increased risk of thrombosis is highly appealing and unique for a coated intravascular device.”
Source: Medindia
